Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05435495 · ClinicalTrials.gov registry record
Mechanisms of Resistance to PSMA Radioligand Therapy
A clinical trial of Prostate Cancer, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 125
- Enrollment target
- 3
- Study locations
NCT05435495: Recruiting study of Prostate Cancer, sponsored by University of California, San Francisco.
NCT05435495 is a study of Prostate Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 125 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05435495, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Primary Outcome
The unit density sphere model will be implemented using OLINDA, a second-generation personal computer software for internal dose assessment in nuclear medicine to measure mean dose across all metastatic lesions. This approach uses the three time-point SPECT/CTs to create a whole-body dose map, which can then be segmented. Using OLINDA, the total dose to each tumor will be calculated as the integral of activity over time estimated out to 500 hours. Dose will be calculated in gray (Gy).
Conditions Studied
Interventions
- PROCEDURE Blood Draw
- PROCEDURE Single-photon emission computed tomography
- PROCEDURE Tumor Biopsy
Study Locations (3)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Memorial Sloan Kettering - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2026-12-31 |
What NCT05435495 shows while recruiting
NCT05435495 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Blood Draw is the first listed.
NCT05435495 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT05435495 about?
NCT05435495 is a clinical study titled "Mechanisms of Resistance to PSMA Radioligand Therapy". This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
What is the current status of trial NCT05435495?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2021-10-21. Estimated completion is 2026-12-31.
What conditions does trial NCT05435495 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05435495?
The interventions under investigation include: Blood Draw (PROCEDURE), Single-photon emission computed tomography (PROCEDURE), Tumor Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05435495?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05435495 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05435495's enrollment target sits among peer trials
125 297th of 735 higher than 438 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI